Funding has been hard to come by in 2023, but some companies have had great success breaking down the walls and securing the cash they need to grow. Last week, companies in artificial intelligence (AI), biotech and space raised more than $2 billion combined. Could this be a sign of bigger things to come in the fourth quarter of 2023 and the new year? Take a closer look at the biggest winners: Anthropic ($1.25B, AI): This San Francisco AI firm, recognized for its AI assistant Claude, has secured
Avalyn Pharma aims to improve treatment of Idiopathic pulmonary fibrosis with inhalable versions of two older oral drugs and it’s now headed for mid-stage testing backed by a Series C financing. Other recent biotech industry financings raised money for research in cancer, immunology, and rare genetic diseases.
In a positive sign for its future success, Harbinger Health Inc. closed a $140 million series B fundraising round, bringing total funds raised since its founding in 2020 to $190 million. The new funds will be used to support completion of the company’s CORE-HH 10,000 participant study of its blood-based multicancer early detection (MCED) test. The company expects to complete enrollment in CORE-HH, a three-part case control, adaptive study with development, validation and longitudinal cohorts in 2024.